Ad
related to: prophylactic
Search results
Smallcap stock jumps 4% after company received approval from GCPL for supply of condoms
Investing.com· 8 hours agoPharma stock engaged in dealing, marketing, and manufacturing rubber contraceptives and allied ...
Cyclosporine Drops Ease Discomfort After Cataract Surgery
Medscape· 8 hours agoProphylactic use of cyclosporine A cationic emulsion eye drops before cataract surgery led to less...
Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine...
Yucaipa News Mirror· 3 days agoPatients who switched to donidalorsen from prior prophylactic treatment also showed 62% further reduction in mean monthly HAE attack rates from baseline, and 84% of patients ...
Hereditary Angioedema Attacks Reduced With Donidalorsen Prophylaxis
MedPage Today· 3 days agoAn antisense oligonucleotide therapy showed efficacy as a prophylactic treatment for hereditary...
Points To Consider For Assessing Lipid Quality For Lipid Nanoparticle Manufacturing
BioresearchOnline· 5 days agoLipid nanoparticles have generated a ton of buzz, but they pose risks that, perhaps, industry and...
Ionis reveals an oasis for HAE patients as RNA med reduces attacks in phase 3
FierceBiotech· 3 days agoEarlier this year, the company announced that donidalorsen had met the primary endpoint of a phase 3...
How To Prevent Breast Cancer
Health.com· 6 days agoBreast cancer occurs when abnormal cells in the breast grow uncontrollably, forming tumors. About one in three cancers that occur in people assigned...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with...
Benzinga· 1 day agoBioCryst Pharmaceuticals, Inc. BCRX today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function ...
First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...
Quincy Herald-Whig· 3 days agoJohnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 1 day agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.